Breaking Finance News

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) target price upped to $45.00, released a research note earlier today by Brean Capital

Having a price of $31.29, Alder Biopharmaceuticals Inc (NASDAQ:ALDR) traded -6.18% lower on the day. With the last stock price up 12.08% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. ALDR has recorded a 50-day average of $32.18 and a two hundred day average of $27.92. Trade Volume was up over the average, with 892,197 shares of ALDR changing hands over the typical 549,722

Brean Capital bumped up the target of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to $45.00 stating a potential upside of 0.44%.

On 09/27/2016, Zacks Investment Research released a statement about Alder Biopharmaceuticals Inc (NASDAQ:ALDR) upped the target price from $0.00 to $38.00 that suggested an upside of 0.11%.

Recent Performance Chart

Alder Biopharmaceuticals Inc (NASDAQ:ALDR)

Alder Biopharmaceuticals Inc has with a one year low of $15.82 and a one year high of $39.43 and has a market capitalization of $0.

A total of 4 brokerages have issued a ratings update on Alder Biopharmaceuticals Inc. Two brokerages rating the company a strong buy, one brokerage rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $47.00.

General Company Details For Alder Biopharmaceuticals Inc (NASDAQ:ALDR)

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushing's disease. It is also developing ALD403 program for migraine prevention.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.